Asset Details
Do you wish to reserve the book?
BITE THERAPY: JUST IN TIME EDUCATION FOR NEWLY APPROVED MEDICATIONS
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
BITE THERAPY: JUST IN TIME EDUCATION FOR NEWLY APPROVED MEDICATIONS
Do you wish to request the book?
BITE THERAPY: JUST IN TIME EDUCATION FOR NEWLY APPROVED MEDICATIONS
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
BITE THERAPY: JUST IN TIME EDUCATION FOR NEWLY APPROVED MEDICATIONS
2025
Overview
Significance & Background: In 2023, 13 new drugs were approved for treatment of a variety of cancers. Additionally, 67 drugs were approved for expanded use or treatment of additional patient populations. One cellular therapy, omidubicel-only, was approved to reduce time to neutrophil recovery in individuals receiving umbilical cord blood transplant after a myeloablative regimen. Medications administered in the outpatient setting may require admission to the inpatient area where nurses are not familiar with the specific agent. BiTE therapy has been available since 2014 (blinatumomab) with additional drug approvals in 2021 through 2024. Once a provider determines that a patient will receive BiTE therapy, approval is required from the hospital Pharmacy and Therapeutics Committee (P&T). After approval, there is not always lead time to schedule formal in-services or have a pharmaceutical representative present on site or via a video call to educate nursing staff. Purpose: The goal of this project was to provide just-in-time education and resources available, specifically on BiTE therapy, for staff prior to the day of treatment. Interventions: Project interventions included creation of a one-page summary specific to the agent. Information included indication, medication safety (toxicity concerns), administration specifics, and events requiring provider notification. A longer presentation addressing information from the package insert and treatment orders/protocols was available for leisurely review. An overview of the product was provided by either the clinical nurse specialist or the nursing professional development generalist prior to initial administration. Results: Information for six agents are currently available on the hospital oncology nursing Microsoft Team site. The site is available to all oncology nursing staff at the facility. A copy of the package insert is also posted on the Team site. Additionally, a binder was provided to the inpatient BMT, hematology, and medical oncology units containing copies of all presentation information. Discussion: In person in-services or sessions offered via a video call can also provide current updates on medications approved by P&T. However, there is not always lead time to schedule these events. Although just-in-time education may not be the preferred delivery method and can be time consuming for the education team and the nursing staff, this method allows for timely staff updates.
Publisher
Oncology Nursing Society
Subject
